Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Use of systemic hormone therapy in BRCA mutation carriers.

Menopause (New York, N.Y.) - 1 Sept 2016

Domchek Susan, Kaunitz Andrew M

Abstract excerpt

As more women are being counseled and tested, clinicians increasingly encounter women with identified BRCA1 and BRCA2 gene mutations. Existing, albeit limited, data indicate that risks of breast cancer are not increased with use of systemic hormone therapy by menopausal BRCA mutation carriers with intact breasts. Young mutation carriers with or without intact breasts should not defer or avoid risk-reducing (and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Risk Factors
Share to Breast Neoplasms
Share to Estrogen Replacement Therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genes, BRCA1

Share to Genes, BRCA2

Share to Menopause

Share to Mutation

Share to Practice Guidelines as Topic

Source

Identifiers

PMID: 27504919
DOI: 10.1097/GME.0000000000000724

Genes

BRCA1
BRCA2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Use of systemic hormone therapy in BRCA mutation carriers.PMID 27504919Read ↗

Hormone replacement therapy in BRCA mutation carriers: how shall we do no harm?Semantic proximity Read ↗

Is Hormone Replacement Therapy Safe in Women With a BRCA Mutation?: A Systematic Review of the Contemporary Literature.Semantic proximity Read ↗

Use of exogenous hormones in those at increased risk for breast cancer: contraceptive and menopausal hormones in gene carriers and other high-risk patients.Semantic proximity Read ↗

The role of estrogens in BRCA1/2 mutation carriers: reflections on the past, issues for the future.Semantic proximity Read ↗

The Role of Hormonal Replacement Therapy in BRCA Mutated Patients: Lights and Shadows.Semantic proximity Read ↗

Barriers to hormone therapy following prophylactic bilateral salpingo-oophorectomy in BRCA1/2 mutation carriers.Semantic proximity Read ↗

Hormone Therapy in Breast Cancer Survivors and Those at High Risk for Breast Cancer.Semantic proximity Read ↗

Factors associated with use of hormone therapy after preventive oophorectomy in BRCA mutation carriers.Semantic proximity Read ↗

Hormone replacement therapy in BRCA mutation carriers and risk of ovarian, endometrial, and breast cancer: a systematic review.Semantic proximity Read ↗

Oral contraceptives, salpingo-oophorectomy and hormone replacement therapy in BRCA1-2 mutation carriers.Semantic proximity Read ↗

Hormone Replacement Therapy After Oophorectomy and Breast Cancer Risk Among BRCA1 Mutation Carriers.Semantic proximity Read ↗

Menopausal hormone therapy and the risk of breast cancer in women with a pathogenic variant in BRCA1 or BRCA2.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.